{"filing":{"accession_number":"0001213900-26-098071","cik":"0001704287","ticker":"BJDX","company_name":"Bluejay Diagnostics, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-01","primary_document":"ea0304864-8k_bluejay.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026098071/ea0304864-8k_bluejay.htm"},"events":[{"id":32059,"run_id":29449,"accession_number":"0001213900-26-098071","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Bluejay Diagnostics entered into a Distribution, Co-Marketing \u0026 Strategic Partnership Agreement with Lovell Government Services on September 1, 2026, establishing exclusive and non-exclusive distribution rights for federal healthcare markets (VA, DoD, IHS). This material strategic partnership creates scalable commercial infrastructure for accessing the U.S. federal healthcare market—representing approximately $237 billion in combined budgets—contingent on FDA clearance.","company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35131,"accession_number":"0001213900-26-098071","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Bluejay entered into a Distribution, Co-Marketing \u0026 Strategic Partnership Agreement with Lovell Government Services on September 1, 2026, establishing exclusive and non-exclusive distribution rights for federal healthcare markets (VA, DoD, IHS). This is a material strategic partnership that creates a scalable commercial infrastructure for accessing the U.S. federal healthcare market—representing approximately $237 billion in combined budgets across VHA, DoD, and IHS—contingent on FDA clearance. While structured as Item 1.01 (Material Definitive Agreement), the substance is a strategic operational partnership rather than an M\u0026A transaction, making operational_other the most precise classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:51:44.084073+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35132,"accession_number":"0001213900-26-098071","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Bluejay Diagnostics announced a strategic distribution and co-marketing partnership with Lovell Government Services to establish federal market access across VA, DoD, Military Health Systems, and IHS. This is a material operational and commercial development that establishes infrastructure for future product commercialization, but it is not a completed M\u0026A transaction, a specific financial obligation, or a governance event. The partnership is designed to position the company for market entry following FDA clearance, representing a significant strategic milestone in building commercial readiness.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:51:44.084073+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35131,"accession_number":"0001213900-26-098071","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Bluejay entered into a Distribution, Co-Marketing \u0026 Strategic Partnership Agreement with Lovell Government Services on September 1, 2026, establishing exclusive and non-exclusive distribution rights for federal healthcare markets (VA, DoD, IHS). This is a material strategic partnership that creates a scalable commercial infrastructure for accessing the U.S. federal healthcare market—representing approximately $237 billion in combined budgets across VHA, DoD, and IHS—contingent on FDA clearance. While structured as Item 1.01 (Material Definitive Agreement), the substance is a strategic operational partnership rather than an M\u0026A transaction, making operational_other the most precise classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:51:44.084073+00:00","company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","filing_date":"2026-09-08"},{"id":35132,"accession_number":"0001213900-26-098071","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Bluejay Diagnostics announced a strategic distribution and co-marketing partnership with Lovell Government Services to establish federal market access across VA, DoD, Military Health Systems, and IHS. This is a material operational and commercial development that establishes infrastructure for future product commercialization, but it is not a completed M\u0026A transaction, a specific financial obligation, or a governance event. The partnership is designed to position the company for market entry following FDA clearance, representing a significant strategic milestone in building commercial readiness.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:51:44.084073+00:00","company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","filing_date":"2026-09-08"}]}